Sign in →

Test Code MISC2MAYOHPFH Hemoglobin F Distribution, Blood

Reporting Name

Hb F Distribution, B

Useful For

Distinguishing large deletional hereditary persistence of fetal hemoglobin from other conditions with increased percentage of fetal hemoglobin (HbF)

 

Determining the distribution of HbF within red blood cells

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Whole Blood EDTA


Ordering Guidance


This test is for hereditary persistence of fetal hemoglobin only. For testing for possible fetal-maternal bleed, see FMB / Fetomaternal Bleed, Flow Cytometry, Blood.



Specimen Required


Only orderable as a reflex. For more information see:

-HAEV1 / Hemolytic Anemia Evaluation, Blood

-HBEL1 / Hemoglobin Electrophoresis Evaluation, Blood

-MEV1 / Methemoglobinemia Evaluation, Blood

-REVE2 / Erythrocytosis Evaluation, Blood

-THEV1 / Thalassemia and Hemoglobinopathy Evaluation, Blood and Serum


Specimen Stability Information

Specimen Type Temperature Time
Whole Blood EDTA Refrigerated 14 days

Reference Values

Only orderable as a reflex. For more information see:

-HAEV1 / Hemolytic Anemia Evaluation, Blood

-HBEL1 / Hemoglobin Electrophoresis Evaluation, Blood

-MEV1 / Methemoglobinemia Evaluation, Blood

-REVE2 / Erythrocytosis Evaluation, Blood

-THEV1 / Thalassemia and Hemoglobinopathy Evaluation, Blood and Serum

 

Reported as: Heterocellular, Homocellular, or Equivocal

Day(s) Performed

Monday through Friday

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

88184

LOINC Code Information

Test ID Test Order Name Order LOINC Value
HPFH Hb F Distribution, B 4579-9

 

Result ID Test Result Name Result LOINC Value
8270 Hb F Distribution, B 4579-9
2104 Interpretation 59466-3

Clinical Information

More than 75% of the hemoglobin in a newborn infant is fetal hemoglobin (HbF); it diminishes over a period of several months to adult levels, reducing to less than 2% by 1 year of age and less than 1% by 2 years of age.

 

Hemoglobin F may constitute 90% of the total Hb in patients with beta-thalassemia major or other combinations of beta thalassemia and fetal Hb (hereditary persistence of fetal hemoglobin: HPFH) variants.

 

Hemoglobin F is often mildly to moderately elevated in sickle cell disease, aplastic anemia, acute leukemia, and myeloproliferative disorders, such as juvenile myelomonocytic leukemia, hereditary spherocytosis, and alpha-thalassemia minor. It is commonly increased in hemoglobinopathies associated with hemolysis. HbF increases to as high as 10% during normal pregnancy. HbF is also increased due to medications such as hydroxyurea, decitabine, and lenalidomide. Elevation in HbF has a been cited as a discriminator between Diamond-Blackfan congenital pure red cell aplasia (elevated) and transient erythroblastopenia of childhood (normal), but whether this simply reflects the chronicity of anemia inherent to the former condition rather than a specific finding is unclear.

 

In the common (large deletional) form of the genetic trait HPFH, all erythrocytes contain HbF. When tested by flow cytometry using specificity for HbF, these HPFH cases display a homocellular distribution pattern of HbF within the red blood cell population. Other causes of increased HbF, including delta beta thalassemia, hydroxyurea, and some nondeletional HPFH variants, typically display a heterocellular distribution of HbF within the erythrocytes, reflecting disparate populations of F cells and cells lacking HbF. Quantification of HbF percentage should be determined prior to flow cytometry of HbF red blood cell distribution to establish the appropriateness of this test. The flow cytometry analysis of elevated HbF levels is useful when HbF percentage is 15% to 35% and the clinical differential diagnosis includes large deletional HPFH. HbF percentages below 15% are likely not due to large deletional HPFH, and the causes of HbF percentages above 35% are better confirmed by molecular and family studies.

Interpretation

Homocellular distribution of fetal hemoglobin (HbF) is found in large deletional hereditary persistence of HbF.

 

Heterocellular distribution is found in delta beta thalassemia, medication induced, and other causes of increased HbF.

 

An equivocal result indicates the pattern is not typical for either a homocellular or heterocellular distribution.

Method Description

This assay uses a flow cytometric method with a monoclonal antibody to fetal hemoglobin (HbF). Specimens are analyzed by single-color flow cytometry using fluorescein anti-HbF. In normal adults, a single peak is seen with minimal fluorescence, which corresponds to HbA. In neonates, a single peak with bright fluorescence is seen, which corresponds to HbF. In cases of hereditary persistence of fetal Hb (HPFH) only, a single peak is observed, which has a fluorescence intensity intermediate between the normal HbA and HbF peaks. This pattern corresponds to the homocellular (pancellular) pattern obtained by the Kleihauer-Betke (K-B) method. In contrast, specimens from infants, transfused neonates, and cases of beta thalassemia or delta/beta thalassemia show both HbA and HbF peaks, corresponding to the heterocellular pattern of the K-B method. In patients with HbS/HPFH, a single peak was observed in contrast to patients with homozygous S in which 2 peaks were observed.(Package insert: Invitrogen Fetal Hemoglobin Test Kit with FITC-conjugated Monoclonal Antibody Directed to HbF. Life Technologies Corporation; MAN 0003641, Rev 3.02, 11/21/2019)

Report Available

3 to 5 days

Reject Due To

Gross hemolysis Reject
Gross lipemia OK
Clotted blood Reject

Method Name

Only orderable as a reflex. For more information see:

-HAEV1 / Hemolytic Anemia Evaluation, Blood

-HBEL1 / Hemoglobin Electrophoresis Evaluation, Blood

-MEV1 / Methemoglobinemia Evaluation, Blood

-REVE2 / Erythrocytosis Evaluation, Blood

-THEV1 / Thalassemia and Hemoglobinopathy Evaluation, Blood and Serum

 

Flow Cytometry

Specimen Minimum Volume

0.5 mL

Secondary ID

8270